ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Trial details
- Registry ID
- NCT07513285
- Drugs studied
- Ibezapolstat
TrialRedline tracks 2 clinical trials sponsored by Acurx Pharmaceuticals Inc.: 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionNCT07513285 | Ibezapolstat | Recruiting | 2027-09-29Estimated |
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542 | Ibezapolstat, Vancomycin | Completed | 2023-10-03Actual |
Names as written in the registry records.
NCT07513285 · Acurx Pharmaceuticals Inc.
Before: Not yet recruiting. After: Recruiting.